ReviewCancer medicine2022

Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory-differentiated thyroid cancer.

Paula Jimenez-FonsecaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.